Growth Financing Cerus has recently secured a substantial debt facility of up to 110 million to support growth and reduce financing costs, presenting an opportunity to discuss financing options, capital equipment investments, and scalable manufacturing enhancements.

ISBT Engagement Active participation in the ISBT congress with company-sponsored events and abstracts indicates a strong emphasis on global blood system innovation; potential to align sales efforts around INTERCEPT Blood System enhancements, training, and clinical evidence packages.

Revenue Momentum Recent quarterly and first-half revenue growth, including product revenue up 10 percent year over year and half-year revenue of approximately 111 million, suggests expanding customer adoption and potential upsell opportunities for expanded services, integrated solutions, or consumables.

Leadership Transition Upcoming leadership change with Vivek Jayaraman promoted to CEO while existing leadership shifts to executive chair, creating an opening for strategic partnerships, channel plans, and executive-ready value propositions aligned to new growth priorities.

Global Footprint Presence in international markets and a Madrid registered base signals opportunities to optimize regional deployment, supply chain resilience, and localized training or service agreements to support global customers and new market entries.